Pierre Soubeyran, Leader of the Oncosphere Nouvelle-Aquitaine project, is a University Professor (University of Bordeaux) and a specialist in Cancer Control Centers at the Bergonié Institute in Bordeaux (Department of Medical Oncology). He obtained his Doctorate in Medicine in 1989, his Diploma of Special Studies in 1989 and his Doctorate of Biological and Medical Sciences (Option: Biology – Health) in 1996. His areas of interest are non-Hodgkin lymphomas, biology molecular and oncogeriatrics.
Since 2013, he has been director of BRIO (Bordeaux Recherche Intégrée en Oncologie), director of the ACTION team (Actions for oncogenesis understanding and target Identification in Oncology) Inserm since 2016. He is also director of research at the Institut Bergonié and since 2018, he is in charge of the oncology structuring project in Nouvelle-Aquitaine: Oncosphere.
He is a member of several learned societies, including: American Society of Clinical Oncology (ASCO, since 2001), American Society of Hematology (ASH, since 1993), European Society of Medical Oncology (ESMO, since 1990), European Society of Therapeutic Radiology and Oncology (ESTRO, since 1987), International Society of Geriatric Oncology (SIOG, since 2002).
He also has several scientific responsibilities: he is a member of the Scientific Steering Committee of the Cancéropôle du Grand Sud-Ouest, since 2007, member of the Strategic Committee and of the Technical Committee of the Data Processing Center (CTD) Clinical Trials in Cancerology of Bordeaux, labeled by the National Cancer Institute, co-coordinator of the Oncogeriatrics Coordination Unit (UCOG), labeled by the National Cancer Institute, co-coordinator of the Regional Thematic Groups “Malignant Hemopathies” and “Oncogeriatrics” of the Network of Cancerology of Aquitaine, member of the Biomedical and Public Health Research Committee (CRBS) of the University Hospital of Bordeaux, member of national or European expert committees for various pharmaceutical laboratories focused on oncogeriatrics (Chugai, Roche, Celgene, AMGEN).
Pr Ingrid ARNAUDIN MORE INFORMATION
PhD Ingrid ARNAUDIN
Ingrid Arnaudin, member of the Steering Committee of the Oncosphere network and co-facilitator of Axis 2 Tumor Microenvironment, is a University Professor at La Rochelle University. She obtained her Doctorate in Biochemistry in 1999 at the University of La Rochelle then her Habilitation to Direct Research in 2008. Her research subjects focus on the discovery of new biomolecules from the natural environment and the development of targeted microenvironmental biotherapies tumor. In particular, she is dedicated to the design and evaluation of structural mimes of heparan sulfate that inhibit the activity of a pro-tumor endoglycosidase, heparanase.
She carries out her scientific activity within the Biotechnologies and Chemistry of Bioresources for Health team of the CNRS 7266 LIENSs unit (La Rochelle University) which has around twenty teacher-researchers and several doctoral and post-doctoral students working the development of pharmacological or nutritional active ingredients of natural origin, mainly derived from or inspired by marine resources (micro- and macro-algae, bacteria). Different families of molecules are obtained (glycomolecules, peptides, polyphenols, pigments, alkaloids). The biological purposes are compounds with an anti-tumor aim, cardio-metabolic regulators, anti-infectives and dermo-active agents.
After leading this team for 7 years, she now co-hosts the unit’s theme of natural substances in oncology. She also has several responsibilities within the La Rochelle community: she is the referent of the University’s “Biotechnologies, agro-food, health” sector, member of the research council and of the university’s academic council, and coordinator of the research project. the Rochelaise Oncosphere.
Bertrand Daignan-Fornier, member of the Steering Committee of the Oncosphere network and leader of Axis1 Fundamental and translational oncogenesis, is the Director of Research at the CNRS. He obtained his Doctorate in Biological and Medical Sciences (Mention Genetics) in 1989 at the University of Paris 6 Pierre et Marie Curie. His research topics are metabolism and its regulation.
Since 2011, he has been director of the Institute of Cellular Biochemistry and Genetics (IBGC, UMR5095 CNRS University of Bordeaux) which has a dozen research teams working on the study of fundamental living mechanisms with two main themes: metabolism energy / mitochondria on the one hand and division, death and cell cycle on the other.
He also has several responsibilities within the Bordeaux community: he is a member of the Management Committee of the Grand Program Cancer project, Deputy Director of the Life and Health Sciences doctoral school and Member of the Council of doctoral schools.
Jean-Luc Feugeas, member of a theoretical physics group of the CELIA Joint Research Unit (Center for intense lasers and applications), has been a researcher at the French Atomic Energy Commission and Alternative Energies (CEA) since 1997. He has a Doctorate in Applied Mathematics and an Habilitation to Direct Research from the University of Bordeaux. He devotes his research work to the study and modeling of the transport of energy sources in matter applied to fusion physics and oncology.
Since 2017, he has been involved in leading the STEM (science, technology, engineering and mathematics) community for oncology in Bordeaux. He carries several responsibilities and commitments in the life of the Bordeaux and regional scientific community: he is in particular a member of the Management Committee of the Major Cancer Program project, member of the Steering Committee of the Oncosphere network and coordinator of the Technological Innovation Axis and member of the Steering Committee of Axis 5 (Technology for health) of the Cancéropôle Grand Sud-Ouest (GSO).
Dr Éric PINAUD MORE INFORMATION
Dr Éric PINAUD
Eric Pinaud, member of the Steering Committee of the Oncosphere network, and involved in the Fundamental and Translational Oncogenesis Axis, is Director of Research at CNRS. After scientific studies at the University of Bordeaux, he joined Michel Cogné’s laboratory between 1996 and 2002 for his DEA and his Doctorate, during which he studied the regulatory elements (enhancers) of the genes of immunoglobulins.
He spent two years post-doctorate at Harvard University (Boston, USA) in the laboratory of Frederick Alt, specialized in the mechanisms of recombination and repair of the DNA of lymphocytes before joining the CNRS in 2004. He is member of the “Cellular Interactions” section of the CNRS national committee between 2009 and 2012. He has been involved in the region since 2017 as a member of the Steering Committee of Axis 2 (Dynamics of the Genome and Cancer) of the Cancéropôle Grand Sud-Ouest ( GSO) and will soon integrate its CA.
Since 2020, he has been deputy director of the CRIBL UMR 7276 CNRS – 1262 Inserm – University of Limoges laboratory (Control of B Immune Response and Lymphoproliferation). This research unit, located in the Biology and Health Research Center in Limoges, is interested in the fundamental mechanisms of B lymphocyte genome remodeling (recombinations and mutations), in the pathophysiology of lymphomas, myelomas, and amyloidosis.
The team he leads in the CRIBL unit studies, at the nucleus and chromatin scale, the molecular events and actors which on the one hand control the genes of immunoglobulins and on the other hand induce collateral damage (mutations and translocations) in oncogenes of the B lineage.
Nicolas Isambert, member of the Steering Committee of the Oncosphere network, is a Medical Oncologist. After being responsible until 2019 for the Early Phases Unit labeled INCa (CLIP²) at the Center-François Leclerc in Dijon, he is currently head of service at the Regional Cancer Center of the CHU de Poitiers where he is responsible for the Department of ‘Therapeutic Innovations / Translational Research in Oncology and Hematology (DITTOH). He graduated in Medical Oncology from the Faculty of Medicine of Dijon, obtained a doctorate in science from the University of Burgundy – Franche-Comté. He is also attached to the INSERM U1084 team “Laboratory of Experimental and Clinical Neurosciences”, brain tumors group of team 1 (Cell therapies in cerebral pathologies). His activity is focused on the development of targeted therapies, new combinations of immunotherapies as well as the management of patients with rare tumors (sarcomas) or breast cancer.
Majid Khatib, member of the Steering Committee of the Oncosphere network, has been the research director at INSERM since 2008, first at St-Louis hospital in Paris and since 2011 at the University of Bordeaux. He obtained his doctorate from Paris Diderot University in 1997, then completed his postdoctoral training at McGill University (Montreal, Canada). From 2002, he ran his own laboratory as an independent researcher at the Ottawa Hospital Research Institute (OHRI) and assistant professor at the University of Ottawa (Ontario, Canada) before joining INSERM.
In 1997 he began to study the early events of metastatic processes and subsequently demonstrated the importance of the proteolytic processing of protein precursors by proprotein convertases in these processes. His work revealed that inhibition of proprotein convertases may represent a new opportunity in cancer therapy. His research team has since discovered and characterized various substrates of these proteases and demonstrated the importance of their maturation in cancer. His laboratory is also interested in identifying small molecules capable of blocking the maturation of proprotein convertase substrates and reducing the malignant phenotype of tumor cells. His findings have been validated by other researchers in different types of cancer, and currently gene therapy suppression of furin convertase expression is being used to treat patients in clinical trials in the United States.
Majid Khatib has published numerous articles and journals and has been invited to present his work by various international and national universities and to edit two books and book chapters bringing together world experts in the field. His team has filed 12 patents resulting directly from his work on proprotein convertases. He has received several national and international awards and distinctions for his research, including the Brigadier-General Hebert Stanley Birkett Memorial Award (Canada), Royal Victoria Hospital Award (RVH, Montreal, Canada), The Canadian Foundation for Innovation (CFI, Ottawa, Canada), Gordon Conference Prize (NH, United States), Avenir (France). He was appointed to represent French research at the Franco-Japanese Frontiers of Science (Kanagawa, Japan) and held the Samuel-De Champlain and FRSQ-INSERM programs for 6 years. Its team was labeled The League against Cancer and obtained the prestigious Jean and Madeleine Schaeverbeke (Fondation de France) prize and Chair of Excellence from the University of Bordeaux. He is a member of numerous scientific associations including AACR (since 2002), Gordon conference (since 2010), ASIP (since 2002). ICS, since (2002), Herpes et Cancer (2004-2009), French Society of Angiogenesis (since 2012), Ethics Committee 73 (since 2010), Interregional Scientific Council East of the League Against Cancer (since 2019). He is also a member of several international expert committees such as South Plains Foundation (Texas, USA), Canadian Breast Cancer Foundation (Canada), CIHR (Canada). FWO (Belgium), Wellcome trust (Great Britain) and SNSF (Switzerland) and national ones such as INCA, ANR, ARC, Languedoc Roussillon region, and PACA region.
Pr Fabrice LALLOUÉ MORE INFORMATION
Pr Fabrice LALLOUÉ
Fabrice Lalloué, member of the Oncosphere Network Steering Committee, co-facilitator of Axis 1 Fundamental and translational oncogenesis and Axis 4 Aging, is a University Professor at the University of Limoges. He obtained his Doctorate in Biology-Health (Mention Neurosciences) in 2001 at the University of Limoges then his Habilitation to Direct Research in 2014. His research subjects are centered on the study of neurotrophin receptors and co-receptors in mechanisms of tumor cell survival and therapeutic resistance. In particular, he seeks to understand the function of extracellular vesicles in the transfer and dissemination of these receptors to cells in the tumor microenvironment. For several years, he has collaborated in transdisciplinary research work with physicists in order to develop new diagnostic tools to characterize tumor cells.
Since 2010, he has been co-director of the EA3842- CAPTuR team (Cell Activation Control, Tumor Progression and Therapeutic Resistance) at the University of Limoges, made up of teacher-researchers, clinicians, doctoral students and post -doctoral fellows working on the mechanisms of therapeutic resistance and tumor cell survival dependent on neurotrophin receptors in 3 cancers (bronchial cancer, brain cancer and colorectal cancer).
He also has various responsibilities at the local level, member of the management board of the Faculty of Sciences and Techniques, co-coordinator of the Oncosphere site Limoges project; at the level of the Cancéropôle Grand Sud-Ouest as a member of the Scientific Steering Committee and member of axis 3 Translational research, from biology to the clinic.
Sébastien Papot, member of the Steering Committee and leader of the Oncosphere project for the Poitiers site, is a University Professor and co-directs the “Organic Synthesis” team at the Poitiers Institute of Environmental Chemistry and Materials. His research work is mainly oriented towards the design of molecular systems programmed to understand, modulate and mimic biological processes. In this context, with his research team, he is studying new therapeutic vectors designed to selectively detect and destroy tumors.
Since 2019, Sébastien Papot has been the President of the Société de Chimie Thérapeutique. He is also the co-founder and CSO of Seekyo, a company created in 2018 that develops drug candidates to fight more effectively against solid cancers.
After her Master’s degree in Communication Strategy and Policy, she completed her first experience in the field of health in the communication department of the Institut Bergonié in Bordeaux.
Since October 2019, Candice has been the Oncosphere Nouvelle-Aquitaine project manager. She assists Pierre Soubeyran in the structuration and animation of the network and contributes to the development and implementation of the network’s communication strategy.
Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site web. Si vous continuez à utiliser ce site, nous supposerons que vous en êtes satisfait.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.